Literature DB >> 1349769

T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset.

A M Miltenburg1, J M van Laar, R de Kuiper, M R Daha, F C Breedveld.   

Abstract

The presence of activated T cells in the synovial membrane of patients with rheumatoid arthritis (RA) suggests a role for these cells in the pathogenesis of the disease. Recent evidence indicates that human T cells may fall into functional categories dependent on their cytokine profile and cytotoxic capacity. The human Th1 subset is cytolytic and produces high levels of IFN-gamma whereas the Th2 type of T cell produces IL-4. In order to investigate whether Th1 or Th2 type cells are present in the inflammatory synovial membrane in RA, a panel of synovial membrane derived T-cell clones (n = 19) was generated and studied functionally. Anti-CD3-induced cytotoxicity assays were performed to demonstrate the cytotoxic potential of clones. Except for two, all clones were cytolytic in this test. Clone cells were activated to initiate cytokine production and assessment of the cytokine levels showed that all clones produced large amounts of IFN-gamma (18 out of 19 clones: over 50,000 pg/ml) whereas IL-4 was absent or present in minimal amounts (17 out of 19 clones: less than 1000 pg/ml). The production of IL-1, IL-2 and IL-6 was variable. The functional characteristics of the clones studied indicate that they may resemble the Th1 subtype of T cells. Our data suggest a relation between Th1-type functions the chronic inflammation characteristic of RA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349769     DOI: 10.1111/j.1365-3083.1992.tb03260.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  50 in total

1.  Streptococcal cell wall induced arthritis: leukocyte activation in extra-articular lymphoid tissue.

Authors:  Donald Kimpel; Tim Dayton; Krishnaswamy Kannan; Robert E Wolf
Journal:  Inflammation       Date:  2003-04       Impact factor: 4.092

2.  Microarray-based gene expression profiling reveals the mediators and pathways involved in the anti-arthritic activity of Celastrus-derived Celastrol.

Authors:  Hua Yu; Shivaprasad H Venkatesha; Kamal D Moudgil
Journal:  Int Immunopharmacol       Date:  2012-06-02       Impact factor: 4.932

3.  Expression of cytokine mRNA in lentivirus-induced arthritis.

Authors:  F Lechner; H R Vogt; H F Seow; G Bertoni; W P Cheevers; U von Bodungen; A Zurbriggen; E Peterhans
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

4.  Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma.

Authors:  Nathan Young; Natallia Mikhalkevich; Ying Yan; Di Chen; Wei-ping Zheng
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

Review 5.  Cytokine therapy in rheumatoid arthritis.

Authors:  J Hermann; M Walmsley; F M Brennan
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Will the increasing prevalence of atopy have a favourable impact on rheumatoid arthritis?

Authors:  J S Gaston
Journal:  Ann Rheum Dis       Date:  1998-05       Impact factor: 19.103

7.  Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines.

Authors:  C S Cleaver; A D Rowan; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

8.  In vitro differentiation of peripheral blood T cells towards a type 2 phenotype is impaired in rheumatoid arthritis (RA).

Authors:  S Asselin; H Conjeaud; D Fradelizi; M Breban
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 9.  The IL-33/ST2 pathway: therapeutic target and novel biomarker.

Authors:  Rahul Kakkar; Richard T Lee
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

Review 10.  The role of the T cell in autoimmune inflammation.

Authors:  Alla Skapenko; Jan Leipe; Peter E Lipsky; Hendrik Schulze-Koops
Journal:  Arthritis Res Ther       Date:  2005-03-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.